echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Avenue's new drug application for non-opioid painkiller tramadol again rejected by the FDA

    Avenue's new drug application for non-opioid painkiller tramadol again rejected by the FDA

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationFan Dongdong

    According to the detailed information of the complete response letter (CRL) issued a few days ago, the US Food and Drug Administration (FDA) once again refused to approve Avenue Therapeutics intravenous injection, the non-opioid painkiller tramadol
    .

    In the new CRL, the FDA stated that when tramadol alone is administered to treat acute pain, the unpredictability and delayed analgesia of intravenous therapy are not enough to prove the benefits of the therapy
    .


    In addition, the FDA stated in the CRL that so far there is not enough data to support the safety and effectiveness of intravenous tramadol and other analgesics in the expected approved population


    In a statement issued by Avenue Therapeutics, the company stated that it "does not agree with the FDA's interpretation of the data in the NDA, and intends to continue to seek regulatory approval for the intravenous drug tramadol
    .


    " This is the second CRL sent by the FDA to Avenue.


    The company resubmitted the NDA in April this year
    .


    Initially, the FDA made a decision to refuse on the grounds that the agency had safety issues


    The drug was submitted to the NDA in December 2019, and positive results from two phase III studies were also submitted
    .


    In addition to an open-label safety study of more than 500 patients receiving 50 mg treatment, these key trials also evaluated the efficacy of intravenous tramadol in patients following bunionectomy and abdominal plastic surgery


    In addition, the initial NDA submission also included data from epidemiological studies on tramadol abuse in the United States and some European countries
    .


    In this study, the researchers found that reports of tramadol abuse were not common, either in absolute amounts or relative to other opioids


    Real data published in the journal Drug and Alcohol Dependence last December compared the misuse and abuse of codeine, morphine, and oxycodone treatments
    .


    The lead research investigator and PhD of Science Janetta L.


    Reference source: FDA Once Again Rejects Avenue Therapeutics' NDA for IV Non-Opioid Painkiller

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.